Ann: Business Development Update, page-15

By my reckoning you're right kipp (Post #: 34528500). It's not a bad thing if current share and note holders maintain the faith and have supported the Co.

I have. I sold some across all my accounts to crystallise some losses, bought some back (mainly at a pip higher) and have exercised my rights. It sounds like I'm not the only clown.

Anyway, the opportunities are there (maybe). The latest presso was more professional than any so far, but there was a couple of things that sh*t me.

I really hated the reference to CBD (no not clyde, cannabidiol). As someone said "it is so 2017" everyone from busted-ass miners, bit-coiners and online porn sites jumped on the THC band wagon, it’s a case of the horse having already bolted. By the way, there may be an opportunity to increase the speed of action, but oro-mucosal will never be as quick as via the lungs and there are a million different methods that users (non-smokers) have available and if pain is the priority then sooner is better. So, I think that reference is very bollocksy.

So is the reference to oestradiol. That's the first time that Carter has published that data. I really hope that was NVDL research rather than something Carter has sanctioned time and money being spent on. Acrux (ACR) has a product Evamist (oestradiol transdermal spray) which has gone nowhere. Maybe it’s the link between HRT and breast cancer Stevo???

Anyway, that’s pure speculation on my part that Carters “scattergun” approach included investing dollars that he didn’t have on these two areas. (Oh, by the way Stevo in Australia it’s called a shotgun).

There seems to be increasing emphasis on David Phillips being the next “great white hope.” Seems he’s responsible for 50 “deals” and a bunch of M&A’s. I just hope that his repertoire isn’t as inflated as Carters employment by Pfizer. He does however seem to have more experience than the rest of the clowns.

I really hate to say this but Stewarts departure from this company, ostensibly under some very sad circumstances, does look somewhat curious.

NDF research target of 4c to 14c looks very ambitious.

The Clemastine fumarate graph is interesting. Sandoz have a generic of this product and by my interpretation of the graph there’s a real benefit that’s been evidenced. This is potentially a good product. Same can be said for the Ondansetron and Zolpi graphs which show great efficacy.

“5 years of explosive growth”- Qué (enter from left little Spanish dude from Faulty Towers)

BD is the new company wank-word. “Suda to invest BD into High Value US market.” Sure we are. “Deals done by F2F and B2B meetings.” FFS. “Suda to employ US based BD Specialist in Q1 FY2019.” Great so we are going to employ another dude (in US dollars). What happened to the other dude that we were advertising for, about 2 weeks before the BerlinFarmer SHTF?

Currently >15 JD/JV opportunities. OK??

Anticipated Milestones. Well I nearly had a heart attack. At some stage people should be held accountable for making ridiculous projections that are clearly aimed at getting money into the company and not about any chance of really occurring. But I guess if pollies can promise the world prior to an election and then deliver nothing then how’s this bollocks any different? Dodgey really and I for one have no faith in this table. (Sorry Marg)

Anyway, I’m still in. I think that at half a cent if you are buying in (new), then it might be good for a one or two bagger.

Of course, all this is worth nought if they only raise $4 MM because that will allow free cash of only 3 months!!!!